Skip to main navigation Skip to search Skip to main content

A Phase I/III Randomized, Double-blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment

Project: Research

Project Details

StatusActive
Effective start/end date07/27/23 → 06/30/26

Funding

  • AstraZeneca Pharmaceuticals LP: $195,072.00